MEDS Financials

Income Statement
MetricQ2 2024Q1 2024Q4 2023Q3 2023Q2 2023
Revenue
18.7K
0
-100.0%
128.7K
-67.2%
392.3K
+7.0%
366.5K
Cost of Revenue
19.4K
0
-100.0%
242.6K
-31.2%
352.7K
+17.8%
299.4K
Gross Profit
-703
0
+100.0%
-113960
-387.8%
39.6K
-41.0%
67.1K
Operating Expenses
1.5M
-72.8%
5.5M
+156.7%
2.1M
+167.0%
801.3K
+20.1%
666.9K
R&D
86.7K
+67.9%
51.6K
+168.9%
-74946
-439.6%
22.1K
-20.0%
27.6K
SG&A
1.2M
-75.8%
5.1M
+267.1%
1.4M
+275.9%
369.7K
-28.1%
514.5K
Operating Income
-1495691
+72.8%
-5492971
-143.7%
-2253597
-195.9%
-761678
-27.0%
-599782
EBITDA
-1323483
+74.3%
-5153424
-632.5%
-703510
-101.4%
-349377
+26.0%
-472161
Net Income
-1833902
-108.6%
21.2M
+282.1%
-11665629
-230.9%
-3525114
-78.5%
-1974878
EPS (Basic)
$-1.30
-106.3%
$20.49
+263.9%
$-12.50
-173.5%
$-4.57
-57.6%
$-2.90
EPS (Diluted)
$-1.30
-107.8%
$16.77
+934.3%
$-2.01
-34.9%
$-1.49
+48.6%
$-2.90
Shares (Diluted)
1.4M
+11.0%
1.3M
-78.2%
5.8M
+145.9%
2.4M
+246.9%
681.2K
DataMeds AI (MEDS) โ€” Financials